Spots Global Cancer Trial Database for hepatic impairment

Every month we try and update this database with for hepatic impairment cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment	NCT05599932	Hepatic Impairm...	Siremadlin	18 Years - 75 Years	Novartis
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function	NCT01443481	Solid Tumors Hepatic Impairm...	Dovitinib	18 Years -	Novartis
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function	NCT01443481	Solid Tumors Hepatic Impairm...	Dovitinib	18 Years -	Novartis
Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment	NCT01632436	Metastatic Canc...	Pixantrone	18 Years -	CTI BioPharma
Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment	NCT05101265	Advanced Solid ... Hepatic Impairm...	Lurbinectedin Lurbinectedin	18 Years -	PharmaMar
Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment	NCT01632436	Metastatic Canc...	Pixantrone	18 Years -	CTI BioPharma
A Comparison Between Child-Pugh and Albumin-Bilirubin Scores	NCT03534843	Rupture, Sponta... Rupture Liver Hepatocellular ... Hepatic Impairm...	Liver resection Transcatheter a...	15 Years - 76 Years	Huazhong University of Science and Technology
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.	NCT04831944	Advanced Malign...	parsaclisib	18 Years - 80 Years	Incyte Corporation
A Pharmacokinetic Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function	NCT06126575	Hepatic Impairm...	Elacestrant dih...	18 Years -	Stemline Therapeutics, Inc.
An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function	NCT01278849	Histologically-...	ASA404	18 Years -	Novartis
INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function	NCT02474537	Hepatic Impairm...	INC280	18 Years - 75 Years	Novartis
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma	NCT04759846	BRAF V600 Mutat... Unresectable Me... Metastatic Mela... Hepatic Impairm...	Encorafenib + B... Encorafenib + B... Encorafenib + B...	18 Years -	Pierre Fabre Medicament
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients	NCT01576406	Advanced Cancer	crizotinib crizotinib crizotinib crizotinib crizotinib	18 Years -	Pfizer
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.	NCT04831944	Advanced Malign...	parsaclisib	18 Years - 80 Years	Incyte Corporation
Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours	NCT00621725	Advanced Cancer Hepatic Impairm...	AZD2171	18 Years -	AstraZeneca
An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function	NCT01278849	Histologically-...	ASA404	18 Years -	Novartis
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment	NCT01949545	Solid Tumors Hematologic Mal... Hepatic Impairm...	Carfilzomib	18 Years -	Amgen
A Pharmacokinetic Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function	NCT06126575	Hepatic Impairm...	Elacestrant dih...	18 Years -	Stemline Therapeutics, Inc.
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function	NCT01443481	Solid Tumors Hepatic Impairm...	Dovitinib	18 Years -	Novartis
A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.	NCT05329623	Small Cell Lung...	JDQ443	18 Years - 75 Years	Novartis
Study of Copanlisib in Hepatic or Renal Impairment	NCT03172884	Hepatic Insuffi...	Copanlisib (ALI...	18 Years - 80 Years	Bayer
Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours	NCT00621725	Advanced Cancer Hepatic Impairm...	AZD2171	18 Years -	AstraZeneca
A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function	NCT04398680	Multiple Myelom...	Belantamab mafo...	18 Years -	GlaxoSmithKline
Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor	NCT03521037	Neoplasms	Rucaparib camsy...	18 Years -	pharmaand GmbH
Hepatic Impairment Study for Lorlatinib in Cancer Patients	NCT03726333	Advanced Cancer...	lorlatinib lorlatinib lorlatinib lorlatinib lorlatinib	18 Years -	Pfizer
Hepatic Impairment Study for Lorlatinib in Cancer Patients	NCT03726333	Advanced Cancer...	lorlatinib lorlatinib lorlatinib lorlatinib lorlatinib	18 Years -	Pfizer
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients	NCT01576406	Advanced Cancer	crizotinib crizotinib crizotinib crizotinib crizotinib	18 Years -	Pfizer

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: